C11orf35 Inhibitors
C11orf35 inhibitors encompass a collection of compounds that indirectly attenuate the activity of C11orf35 through their action on various cellular signaling pathways. For example, LY294002 and Wortmannin, potent inhibitors of PI3K, would likely lead to the inhibition of C11orf35 if it is functionally linked to the PI3K/Akt pathway. By obstructing this pathway, these inhibitors would prevent the downstream signaling required for C11orf35's activity, thus leading to its functional suppression. This effect is critical as the PI3K/Akt pathway is instrumental in controlling cell growth and survival, and its inhibition has far-reaching consequences on cellular homeostasis.
Further, compounds like U0126 and PD98059 act as MEK inhibitors to obstruct the MAPK/ERK pathway. If C11orf35's functionality is dependent on the MAPK/ERK pathway, then the use of U0126 and PD98059 would compromise its activity by blocking the upstream signaling events. The MAPK/ERK pathway plays a crucial role in controlling cell division, differentiation, and response to stress. Thus, the inhibition of this pathway could have significant effects on cellular functions where C11orf35 is involved.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that blocks PI3K/Akt signaling. C11orf35 activity could be reduced by this compound if C11orf35 is part of or regulated by the PI3K/Akt pathway, leading to its functional inhibition through disrupted signal transduction. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the MAPK/ERK pathway. If C11orf35 functions downstream of this pathway or relies on it for activation, its activity would be inhibited due to the suppression of ERK signaling, which is crucial for various cellular responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, a key player in the stress response. C11orf35 could be impacted by this compound if it operates within the p38 MAPK pathway or if p38 MAPK influences factors that modulate the functional activity of C11orf35. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Similar to LY294002, if C11orf35 is associated with the PI3K/Akt pathway, inhibition by Wortmannin would lead to functional inhibition of C11orf35 by preventing necessary signaling events required for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that affects cell growth and proliferation pathways. If C11orf35 is involved in mTOR signaling, Rapamycin would lead to its functional inhibition by disrupting the pathway that is possibly essential for C11orf35's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in apoptosis and proliferation. If C11orf35's activity is regulated through JNK signaling, then SP600125 would diminish its functional activity by disrupting JNK-mediated cellular processes. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a specific Akt inhibitor. If C11orf35 relies on Akt-mediated signaling for its function, then inhibition of Akt by Triciribine would directly lead to a decrease in C11orf35's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Similar to U0126, PD98059 is a MEK inhibitor that would hinder the MAPK/ERK pathway. Any functional dependence of C11orf35 on this pathway would be compromised, resulting in its inhibition. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is a potent Akt inhibitor. It would inhibit C11orf35 by blocking Akt signaling if C11orf35 requires Akt activation for its function, thereby preventing the phosphorylation and activation events needed for its activity. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of ERK signaling. Inhibition of this pathway would lead to functional inhibition of C11orf35 if it is downstream or regulated by ERK-mediated signaling. | ||||||